AKBA Overview
Upcoming Projects (AKBA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AKBA)
-
Discussing CKD and the use of Akebia's Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease in adult patients on dialysis
Ticker: AKBA
Executed On: Jan 27, 2025 at 02:00 PM EST -
Discussing Akebia’s Vadadustat for the treatment of anemia due to chronic kidney disease (CKD), ahead of the PDUFA date: March 29, 2022
Ticker: AKBA
Executed On: Mar 14, 2022 at 03:00 PM EDT
Upcoming & Overdue Catalysts (AKBA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AKBA)
-
Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
Ticker: AKBA
Occurred on: Aug 08, 2016
Strategic Initiatives (AKBA)
-
Cyclerion Therapeutics (CYCN) Announces $585 million Global Licensing Agreement with Akebia Therapeutics (AKBA) for Praliciguat
Tickers: CYCN, AKBA
Announcement Date: Jun 04, 2021 -
Akebia Therapeutics (AKBA) Announces Exclusive License Agreement with Janssen Pharma (JNJ) for Portfolio Targeting Hypoxia-Inducible Factors (HIF)
Tickers: AKBA, JNJ
Announcement Date: Feb 13, 2017 -
Otsuka (OTSKY) and Akebia (AKBA) Announce U.S Collaboration and License Agreement for Vadadustat in Treatment of Anemia in Patients with Chronic Kidney Disease
Tickers: AKBA, OTSKY
Announcement Date: Dec 13, 2016
